FDA Clearance Tracker · K171493
MegaVac Mechanical Thrombectomy System
Last checked: Nov 20, 2026Latest source record: Aug 10, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Aug 10, 2017
Substantially Equivalent
Time to decision
80 days
Received May 22, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K171493
- Device name
- MegaVac Mechanical Thrombectomy System
- Applicant
- Capture Vascular, Inc.
- Applicant location
- Mountain Village, CO
- Received
- May 22, 2017
- Decided
- Aug 10, 2017
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.5150
- Specialty
- CardiologyInterventional Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QEX. The earliest in FDA's data is K163618, decided May 24, 2017.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K171493
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Capture Vascular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.